Clincosm LogoSign in Get a demo

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of TB-840 in Healthy Subjects

Sponsor
Therasid Bioscience (Industry)
Overall Status
Recruiting
CT.gov ID
NCT05045534
Collaborator
(none)
88
Enrollment
1
Location
11
Arms
13.5
Anticipated Duration (Months)
6.5
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This study is a dose block-randomized, double-blind, placebo-controlled, single- and multiple-ascending dose study. For each dose group, 6 subjects will be randomly assigned to the test group (TB-840) and 2 subjects will be randomly assigned to the control group (placebo). Adverse event (AE) monitoring, physical examination, vital signs, ECG, clinical laboratory test will be done for safety and tolerability assessment, and blood and urine samples will be collected for Pharmacokinetic (PK) assessment.

Condition or Disease Intervention/Treatment Phase
  • Drug: Comparison of TB-840 treatment with Placebo
 Phase 1

Study Design

Study Type:
Interventional
Anticipated Enrollment :
88 participants
Allocation:
Randomized
Intervention Model:
Sequential Assignment
Masking:
Double (Participant, Investigator)
Primary Purpose:
Treatment
Official Title:
A Dose Block-randomized, Double-blind, Placebo Controlled, Single-/Multiple-dosing, Dose-escalation Phase 1 Clinical Trial to Investigate the Safety, Tolerability, Pharmacokinetic Characteristics of TB-840 (NASH Treatment Candidate) After Oral Administration in Healthy Subjects
Actual Study Start Date :
Sep 14, 2021
Anticipated Primary Completion Date :
Oct 31, 2022
Anticipated Study Completion Date :
Oct 31, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Cohort 1 Single Dose SD1 (first dose)

Group SD1 a first single dose of TB-840(n=6) or placebo(n=2)

Drug: Comparison of TB-840 treatment with Placebo
Single dose or Multiple Dose of TB-840 treatment
Other Names:
  • TB-840

    		•
    Experimental: Cohort 2 Single Dose SD2 (second dose)

    Group SD2 a first single dose of TB-840(n=6) or placebo(n=2)

    Drug: Comparison of TB-840 treatment with Placebo
    Single dose or Multiple Dose of TB-840 treatment
    Other Names:
  • TB-840

    		•
    Experimental: Cohort 3 Single Dose SD3 (third dose)

    Group SD3 a first single dose of TB-840(n=6) or placebo(n=2)

    Drug: Comparison of TB-840 treatment with Placebo
    Single dose or Multiple Dose of TB-840 treatment
    Other Names:
  • TB-840

    		•
    Experimental: Cohort 4 Single Dose SD4 (fourth dose)

    Group SD4 a first single dose of TB-840(n=6) or placebo(n=2)

    Drug: Comparison of TB-840 treatment with Placebo
    Single dose or Multiple Dose of TB-840 treatment
    Other Names:
  • TB-840

    		•
    Experimental: Cohort 5 Single Dose SD5 (fifth dose)

    Group SD5 a first single dose of TB-840(n=6) or placebo(n=2)

    Drug: Comparison of TB-840 treatment with Placebo
    Single dose or Multiple Dose of TB-840 treatment
    Other Names:
  • TB-840

    		•
    Experimental: Cohort 6 Single Dose SD6 (sixth dose)

    Group SD6 a first single dose of TB-840(n=6) or placebo(n=2)

    Drug: Comparison of TB-840 treatment with Placebo
    Single dose or Multiple Dose of TB-840 treatment
    Other Names:
  • TB-840

    		•
    Experimental: Cohort 7 Single Dose SD7 (seventh dose)

    Group SD7 a first single dose of TB-840(n=6) or placebo(n=2)

    Drug: Comparison of TB-840 treatment with Placebo
    Single dose or Multiple Dose of TB-840 treatment
    Other Names:
  • TB-840

    		•
    Experimental: Cohort 8 Single Dose SD8 (eighth dose)

    Group SD8 a first single dose of TB-840(n=6) or placebo(n=2)

    Drug: Comparison of TB-840 treatment with Placebo
    Single dose or Multiple Dose of TB-840 treatment
    Other Names:
  • TB-840

    		•
    Experimental: Cohort 9 : Mutiple Dose MD1

    Group MD1 a first multiple dose of TB-840(n=6) or placebo(n=2)

    Drug: Comparison of TB-840 treatment with Placebo
    Single dose or Multiple Dose of TB-840 treatment
    Other Names:
  • TB-840

    		•
    Experimental: Cohort 10 : Mutiple Dose MD2

    Group MD2 a first multiple dose of TB-840(n=6) or placebo(n=2)

    Drug: Comparison of TB-840 treatment with Placebo
    Single dose or Multiple Dose of TB-840 treatment
    Other Names:
  • TB-840

    		•
    Experimental: Cohort 11 : Mutiple Dose MD3

    Group MD3 a first multiple dose of TB-840(n=6) or placebo(n=2)

    Drug: Comparison of TB-840 treatment with Placebo
    Single dose or Multiple Dose of TB-840 treatment
    Other Names:
  • TB-840

    		•

    Outcome Measures

    Primary Outcome Measures

    1. Number of participants with treatment-related adverse events as assessed by CTCAE v5.03 [Up to 10 days from single ascending dose]

      Incidences of treatment-emergent adverse events

    2. Number of participants with treatment-related adverse events as assessed by CTCAE v5.03 [Up to 14 days from multiple ascending dose]

      Incidences of treatment-emergent adverse events

    Secondary Outcome Measures

    1. Maximum concentration of drug in plasma[Cmax] [Up to 4 days from single ascending dose]

      Pharmacokinetic Profile of TB-840

    2. Maximum concentration of drug in plasma[Cmax] [Up to 8 days from multiple ascending dose]

      Pharmacokinetic Profile of TB-840

    3. Area under the plasma drug concentration-time curve[AUC] [Up to 4 days from single ascending dose]

      Pharmacokinetic Profile of TB-840

    4. Area under the plasma drug concentration-time curve[AUC] [Up to 8 days from multiple ascending dose]

      Pharmacokinetic Profile of TB-840

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    19 Years to 45 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:

    • Healthy adults aged ≥ 19 and ≤ 45 years at the time of screening visit

    • BMI of ≥ 18.0 and ≤ 27.0 kg/m2 at the time of screening visit

    • Clinically confirmed as healthy based on the medical history, physical examination, vital signs, electrocardiography (ECG), and proper laboratory tests (Subjects with values out of the normal range may participate in the study if they are deemed clinically insignificant by the investigator.)

    • Agree to use medically acceptable methods of contraception by participant, his/her spouse, or partner and not to donate sperm or oocyte from the date of the first dose of the investigational product (IP) until 90 days after the last dose of the IP

    • Examples of medically acceptable methods of contraception

    • Females (females who use oral hormonal contraceptives and subcutaneous hormonal contraceptive implants may be excluded from the study)

    • Use of an intrauterine device with a proven pregnancy failure rate

    • Use of barrier method with spermicide

    • Surgical sterilization (salpingectomy/tubal ligation, hysterectomy, etc.)

    • Males

    • Use of barrier method with spermicide

    • Surgical sterilization (vasectomy, vasoligation, etc.)

    • Voluntarily decided to participate in the study and provided written consent to comply with the protocol

    Exclusion Criteria:

    • Current or history of a clinically significant hepatic, renal, gastrointestinal, respiratory, musculoskeletal, endocrine, neuropsychiatric, hemato-oncological, or cardiovascular disease

    • History of gastrointestinal diseases (e.g., Crohn's disease, ulcer, etc.) or surgery (excluding simple appendectomy or hernia repair) that may affect the absorption of the investigational products

    • History of clinically significant hypersensitivity to drugs containing RORα agonist or other ingredients of the same class, or other drugs (aspirin and non-steroidal anti-inflammatory drugs, antibiotics, etc.)

    • History of drug abuse or positive result from urine drug screening of drugs with concerns of drug abuse

    • Subjects with any of the following results at the time of screening visit:

    • Systolic blood pressure: < 90 mmHg or > 140 mmHg

    • Diastolic blood pressure: < 50 mmHg or > 90 mmHg

    • Heart rate: < 50 bpm or > 100 bpm

    • AST: > x 1.5 ULN

    • ALT: > x 1.5 ULN

    • ALP: > x 1.5 ULN

    • T.bil: > x 1.5 ULN

    • γ-GT： > x 1.5 ULN

    • Serum creatinine: > x 1.5 ULN

    • Participated in another bioequivalence study or clinical study and have been exposed to an investigational product within 6 months prior to the date of the first dose of this study

    • Donated whole blood within 2 months or blood components within 1 month, or received blood transfusion within 1 month prior to the date of the first dose of this study

    • Use of drug-metabolizing enzyme inducer or inhibitor such as barbiturates within 1 month prior to the date of the first dose of this study

    • Consumption of caffeine- or grapefruit-containing foods or beverages within 3 days prior to the date of the first dose of this study

    • Use of any prescription drugs or herbal medicines within 1 month, or any over-the-counter (OTC) drugs within 1 week prior to the date of the first dose of this study (Subjects may participate in the study if such use is judged not to significantly affect the assessment of safety and pharmacokinetics by the investigator.)

    • Excessive intake of caffeine, excessive intake of alcohol, or heavy smoking (caffeine

    5 units/day, alcohol > 21 units/week [1 unit = 10 mL of pure alcohol], smoking > 10 cigarettes/day)

    • Unable to consume meals provided by the study site

    • Prior participation in this study

    • Positive result in serology tests (hepatitis B tests, human immunodeficiency virus [HIV] tests, hepatitis C tests, or syphilis tests [RPR])

    • Determined inappropriate for the study by the investigator

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Therasid Bioscience Seongnam-si Gyeonggi-do Korea, Republic of 13488

    Sponsors and Collaborators

    • Therasid Bioscience

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Therasid Bioscience
    ClinicalTrials.gov Identifier:
    NCT05045534
    Other Study ID Numbers:
    • TB-840-PRT-01
    First Posted:
    Sep 16, 2021
    Last Update Posted:
    Oct 15, 2021
    Last Verified:
    Sep 1, 2021
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No

    Study Results

    No Results Posted as of Oct 15, 2021